

# MEDIA RELEASE - 23 AUGUST, 2021

## FINANCIAL RESULTS FOR THE FULL YEAR ENDED 30 JUNE 2021

### 1. Summary

- Revenue growth of 28% to A\$8.8 billion.
- EBITDA growth of 81% to A\$2.6 billion.
- Net profit growth of 149% to A\$1.3 billion.
- Sonic Healthcare is playing a crucial role in combating the COVID-19 pandemic in its markets, whilst continuing to provide its usual essential healthcare services, with ~138 million patients served globally in FY2021.
- Approximately 30 million COVID-19 PCR tests have been performed to date in ~60 Sonic laboratories globally, and Sonic has become Australia's largest non-government COVID vaccination provider.
- Significant revenue and earnings contribution in FY2021 from COVID-19 testing.
- COVID-19 testing capabilities supported by Sonic's Medical Leadership culture and decades of investment in people and infrastructure.
- COVID-19 PCR test volumes lower in H2 versus H1 but now increasing with spread of the Delta variant.
- FY2021 global base business revenue (ex-COVID testing) up 6% versus FY2020 and 4% versus FY2019 (pre-pandemic).
- Margin accretion in both laboratory and imaging divisions.
- Balance sheet set for growth by acquisition, with gearing at record low level and ~A\$1.5 billion of liquidity currently available (pre-interim dividend and settlement of Canberra Imaging Group acquisition).
- Progressive dividend policy maintained, increase of 4 cents (8%) to 55 cents for the FY2021 Final Dividend. FY2021 Final Dividend franked to 65% (previously 30%). Total dividends for the year up 7% on the prior year.
- Outstanding achievement by Sonic's 38,000 global staff, working in unrelenting and difficult conditions.

### 2. Commentary

Sonic Healthcare today reported a statutory net profit for the full year to 30 June 2021 of A\$1.3 billion, on revenues of A\$8.8 billion.

Sonic's CEO, Dr Colin Goldschmidt, said: "Sonic Healthcare's strong performance in the 2021 financial year reflects the heroic efforts of our 38,000 staff around the world, galvanised by our Medical Leadership culture, to meet the ever-evolving demands of providing seamless essential healthcare services for 138 million patients during a pandemic. I wish to sincerely thank each one of our staff for their unwavering commitments to our patients, our communities and to Sonic Healthcare.

"As a global healthcare organisation, we have continued to play a major role in combating the COVID-19 pandemic, by providing 30 million PCR tests and over 2 million serology tests to date. We are also proud to be the largest non-government provider of COVID-19 vaccinations in Australia. These contributions would not have been possible without the investments in people and infrastructure that Sonic has made over more than two decades. The thought-leadership and innovation provided by our pathologists and scientists has been invaluable, as has the flexibility, dedication and courage of our managers and other staff. Our medical centres, specimen collection and drive-through centres, courier networks, laboratories, IT systems, and supply chains have all been essential to conduct the high quality, high volume COVID-related services we continue to provide. "Whilst a huge amount of time and effort has gone into combating the pandemic, we have never lost sight of the importance of continuing to provide our usual high quality medical diagnostic services. Whilst our total revenue grew 28% in FY2021, our base business revenue grew by 6% on a like-for-like basis. The base business has become increasingly resilient to impacts of pandemic waves and benefits from our geographical and business diversification.

"In total, excluding currency movements, Sonic's laboratory operations achieved organic revenue growth of 37%, enhanced by COVID-19 testing, and EBITDA growth of 97%, showing strong operating leverage. Our Imaging division's revenue growth of 19% and EBITDA growth of 24% was also very pleasing.

"In addition to organic growth, Sonic continues to focus on synergistic acquisitions and other growth opportunities, supported by our current record low gearing levels, geographic footprint, leading market positions and brands, and our deeply embedded Medical Leadership culture. We were delighted to recently announce the pending acquisition of Canberra Imaging Group, following on from our move in March 2021 to majority ownership of Epworth Medical Imaging. We are actively considering further acquisition opportunities, as well as bidding for a number of outsourcing contracts."

#### **Dr Colin Goldschmidt**

Chief Executive Officer / Managing Director Sonic Healthcare Limited Ph.: (02) 9855 5333

This announcement has been authorised by the Board of Directors of Sonic Healthcare Limited – please refer to the contact details above.

For further information regarding the result, please refer to Dr Goldschmidt's PowerPoint Presentation and to Sonic's Appendix 4E Preliminary Final Report, both of which will be posted on the Sonic Healthcare website by 9.00am, 23 August, 2021 (www.sonichealthcare.com).

#### Forward-looking statements

This media release may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by Governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts, unexpected growth in costs and expenses and the progress of the COVID-19 pandemic. The statements being made in this media release do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare. No representation, warranty or assurance (express or implied) is given or made in vertaintion to any underlying assumption or that any forward-looking statement will be or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be forward-looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward-looking statements.